Limited ResearchGrowth Hormone

Tesa/IPA Protocol

Tesa-IPA

Tesamorelin + Ipamorelin GH Secretagogue Blend

Half-life

Not reported

Chain length

Not applicable (peptide combination)

Reference frequency

Once daily (evening preferred) or twice daily for advanced protocols

Research overview

DoseGear research brief

The Tesa/IPA blend combines two complementary growth hormone secretagogues: Tesamorelin (a GHRH analog that stimulates GH release from the pituitary) and Ipamorelin (a selective ghrelin mimetic/GHRP that amplifies GH pulses). This combination addresses both the GHRH and GHRP pathways for synergistic GH release. Common formulations include 5mg/5mg (1:1 ratio) and 10mg/3mg (higher Tesamorelin) variants. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, while Ipamorelin remains investigational.

Mechanism of action

The blend leverages two distinct GH-releasing pathways: Tesamorelin is a synthetic GHRH analog that directly stimulates growth hormone-releasing hormone receptors on pituitary somatotrophs, triggering GH synthesis and secretion in a pulsatile, physiological manner. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that amplifies GH pulses without significantly affecting cortisol or prolactin. Together, they produce synergistic GH release greater than either compound alone, while maintaining the body's natural feedback mechanisms.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Tesamorelin and ipamorelin combination; a specific developer is not established.

What it is researched for

Proposed combined growth-hormone-secretagogue and metabolic applications through GHRH and ghrelin-receptor stimulation.

Research observation window

Not reported for the combination; the cited 26-week trial concerns tesamorelin alone.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

No sourced lyophilized-vial injectable protocol is listed for this profile.

Safety context

Reported side effects

Injection site reactions (redness, itching)
Water retention (usually transient)
Tingling or numbness in extremities
Joint stiffness
Increased hunger (Ipamorelin effect)

Contraindications & cautions

Active malignancy (GH may promote tumor growth)
Diabetic retinopathy
Pregnancy or breastfeeding
Pituitary disorders
Hypersensitivity to components

Scientific references

01
Metabolic effects of a growth hormone-releasing factor in patients with HIV
Scientific citationMetabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine (2007).
02
Ipamorelin, the first selective growth hormone secretagogue
Scientific citationIpamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology (1998).
03
GHRH + GHRP Synergy
Scientific citationGHRH + GHRP Synergy. .
04
No Published Studies on Tesa/IPA Combination
Scientific citationNo Published Studies on Tesa/IPA Combination. N/A (2024).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Growth Hormone